174 related articles for article (PubMed ID: 21503919)
1. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.
Azakami T; Hayes CN; Sezaki H; Kobayashi M; Akuta N; Suzuki F; Kumada H; Abe H; Miki D; Tsuge M; Imamura M; Kawakami Y; Takahashi S; Ochi H; Nakamura Y; Kamatani N; Chayama K
J Med Virol; 2011 Jun; 83(6):1048-57. PubMed ID: 21503919
[TBL] [Abstract][Full Text] [Related]
2. Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients.
Ahmed WH; Furusyo N; Zaky S; Eldin AS; Aboalam H; Ogawa E; Murata M; Hayashi J
World J Gastroenterol; 2013 Mar; 19(9):1387-95. PubMed ID: 23538996
[TBL] [Abstract][Full Text] [Related]
3. ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.
Matsuura K; Tanaka Y; Watanabe T; Fujiwara K; Orito E; Kurosaki M; Izumi N; Sakamoto N; Enomoto N; Yatsuhashi H; Kusakabe A; Shinkai N; Nojiri S; Joh T; Mizokami M
J Viral Hepat; 2014 Jul; 21(7):466-74. PubMed ID: 24750345
[TBL] [Abstract][Full Text] [Related]
4. Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy.
Amjed S; Saleem HGM; Ullah S; Latif S; Shabana ; Jafar J; Waqar AB
BMC Infect Dis; 2024 Mar; 24(1):301. PubMed ID: 38468199
[TBL] [Abstract][Full Text] [Related]
5. Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients.
Nishimura T; Osaki R; Shioya M; Imaeda H; Aomatsu T; Takeuchi T; Okumura Y; Fujiyama Y; Andoh A
Mol Med Rep; 2012 Feb; 5(2):517-20. PubMed ID: 22052220
[TBL] [Abstract][Full Text] [Related]
6. The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients.
Liu Z; Wang S; Qi W; Wang X; Sun D; Wang H; Zhang Y; Li Z; Zhu L; Zhao P; Guo H; Zhou C; Wang J
Medicine (Baltimore); 2017 Jul; 96(29):e7554. PubMed ID: 28723780
[TBL] [Abstract][Full Text] [Related]
7. ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C.
El Raziky M; Zayed NA; Abdel Baki A; Mansour SA; Shahin RMH
J Med Virol; 2017 Oct; 89(10):1823-1829. PubMed ID: 28480960
[TBL] [Abstract][Full Text] [Related]
8. ITPA gene variant may protect against anemia induced during pegylated interferon alfa and ribavirin combination treatment in Ukrainian patients with chronic hepatitis C.
Kucherenko A; Pampukha V; Bobrova I ; Moroz L; Livshits L
Tsitol Genet; 2015; 49(2):38-41. PubMed ID: 26030972
[TBL] [Abstract][Full Text] [Related]
9. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.
Ogawa E; Furusyo N; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Oct; 59(4):667-74. PubMed ID: 23707372
[TBL] [Abstract][Full Text] [Related]
10. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.
Suzuki F; Suzuki Y; Akuta N; Sezaki H; Hirakawa M; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Chayama K; Kamatani N; Nakamura Y; Miyakawa Y; Kumada H
Hepatology; 2011 Feb; 53(2):415-21. PubMed ID: 21246582
[TBL] [Abstract][Full Text] [Related]
11. ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.
Morio K; Imamura M; Kawakami Y; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Makokha GN; Ochi H; Amano H; Arataki K; Moriya T; Ito H; Tsuji K; Kohno H; Waki K; Tamura T; Nakamura T; Chayama K;
J Gastroenterol; 2017 Jun; 52(6):746-753. PubMed ID: 27822709
[TBL] [Abstract][Full Text] [Related]
12. Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
Tahata Y; Hiramatsu N; Oze T; Urabe A; Morishita N; Yamada R; Yakushijin T; Hosui A; Oshita M; Kaneko A; Hagiwara H; Mita E; Ito T; Yamada Y; Inada M; Katayama K; Tamura S; Imai Y; Hikita H; Sakamori R; Yoshida Y; Tatsumi T; Hayashi N; Takehara T
J Med Virol; 2016 Oct; 88(10):1776-84. PubMed ID: 26991414
[TBL] [Abstract][Full Text] [Related]
13. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.
Kurosaki M; Tanaka Y; Tanaka K; Suzuki Y; Hoshioka Y; Tamaki N; Kato T; Yasui Y; Hosokawa T; Ueda K; Tsuchiya K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Matsuura K; Sugauchi F; Enomoto N; Nishida N; Tokunaga K; Mizokami M; Izumi N
Antivir Ther; 2011; 16(5):685-94. PubMed ID: 21817190
[TBL] [Abstract][Full Text] [Related]
14. Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.
Kurosaki M; Tanaka Y; Nishida N; Sakamoto N; Enomoto N; Matsuura K; Asahina Y; Nakagawa M; Watanabe M; Sakamoto M; Maekawa S; Tokunaga K; Mizokami M; Izumi N
J Med Virol; 2013 Mar; 85(3):449-58. PubMed ID: 23297176
[TBL] [Abstract][Full Text] [Related]
15. Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients.
Scherzer TM; Stättermayer AF; Stauber R; Maieron A; Strasser M; Laferl H; Schwarzer R; Datz C; Rutter K; Beinhardt S; Steindl-Munda P; Hofer H; Ferenci P
J Hepatol; 2013 Nov; 59(5):964-71. PubMed ID: 23850877
[TBL] [Abstract][Full Text] [Related]
16. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.
D'Avolio A; De Nicolò A; Cusato J; Ciancio A; Boglione L; Strona S; Cariti G; Troshina G; Caviglia GP; Smedile A; Rizzetto M; Di Perri G
Antiviral Res; 2013 Oct; 100(1):114-9. PubMed ID: 23933495
[TBL] [Abstract][Full Text] [Related]
17. Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.
Domingo P; Guardiola JM; Salazar J; Torres F; Mateo MG; Pacho C; Del Mar Gutierrez M; Lamarca K; Fontanet A; Martin J; Muñoz J; Vidal F; Baiget M
Antimicrob Agents Chemother; 2012 Jun; 56(6):2987-93. PubMed ID: 22430973
[TBL] [Abstract][Full Text] [Related]
18. Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism.
Akamatsu S; Hayes CN; Tsuge M; Murakami E; Hiraga N; Abe H; Miki D; Imamura M; Ochi H; Chayama K;
J Viral Hepat; 2015 Feb; 22(2):166-74. PubMed ID: 24930407
[TBL] [Abstract][Full Text] [Related]
19. Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.
Pineda-Tenor D; García-Álvarez M; Jiménez-Sousa MA; Vázquez-Morón S; Resino S
J Transl Med; 2015 Oct; 13():320. PubMed ID: 26438033
[TBL] [Abstract][Full Text] [Related]
20. Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy.
Kozuka R; Hai H; Teranishi Y; Motoyama H; Kawamura E; Hagihara A; Uchida-Kobayashi S; Morikawa H; Enomoto M; Murakami Y; Kawada N; Tamori A
J Gastroenterol Hepatol; 2017 Aug; 32(8):1495-1502. PubMed ID: 28109022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
